Why Annovis Bio, Inc.’s (ANVS) Stock Is Down 5.25%
As of Thursday, October 08, Annovis Bio, Inc.’s ANVS share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Commentary & Analysis
Why Annovis Bio, Inc.’s (ANVS) Stock Is Down 6.69%
As of Thursday, October 01, Annovis Bio, Inc.’s ANVS share price has dipped by 6.69%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Annovis Bio, Inc.’s (ANVS) Stock Is Up 7.25%
As of Monday, September 28, Annovis Bio, Inc.’s ANVS share price has surged by 7.25%, which has investors questioning if this is right time to sell.Michael Rose
Why Annovis Bio, Inc.’s (ANVS) Stock Is Up 5.97%
As of Tuesday, September 22, Annovis Bio, Inc.’s ANVS share price has surged by 5.97%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Annovis Bio, Inc.’s (ANVS) Stock Is Down 14.12%
As of Thursday, September 03, Annovis Bio, Inc.’s ANVS share price has dipped by 14.12%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ANVS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $43.5 | $232.8 | 15% |
|
| Shares Out (Mil) | 37.5 | 53.4 | 41% |
|
| Institutional Ownership | 66.7% | 92.9% | 41% |
|
| Float (Mil) | 37.9 | 41.2 | 40% |
|
| Beta | 1.24 | 0.96 | 72% |
|
| Avg Daily Volume (000s) | 629 | 490 | 62% |
|
| Price Change (52-week) |
(52.6%) | 48.2% | 19% |
|
| Growth | ANVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (39.4%) | (10.1%) | 10% |
|
| EPS (5yr) | (10.0%) | 15.8% | 21 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (19.2%) | (15.7%) | 35% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.330) | ($1.450) | ($0.860) | |
| Month Ago EPS | ($0.330) | ($1.450) | ($0.860) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.370) | ($1.690) | ($0.885) | |
| Year/Year Chg | (17.5%) | 3.3% | 42.5% | |
| Financials | ANVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($50) | ($44) | 16% |
|
| EPS (TTM) | ($1.790) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($43) | ($33) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $32 | $174 | 14% |
|
| Valuation | ANVS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.22 | na |
|
| P/E | na | 20.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ANVS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (227.7%) | (47.3%) | 2% |
|
| ROE | (703.7%) | (53.3%) | 1% |
|
| Liabilities to Assets | 119.3% | 29.4% | 97% |
|
| F-Score | 1 | 2 | 1% |
|
Annovis Bio, Inc. did not pass any screens on 10/28/2026.
